Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational, multicentre, randomized, open-label, paralle...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohnloser, Stefan H, Camm, John, Cappato, Riccardo, Diener, Hans-Christoph, Heidbüchel, Hein, Mont, Lluís, Morillo, Carlos A, Abozguia, Khalid, Grimaldi, Massimo, Rauer, Heiko, Reimitz, Paul-Egbert, Smolnik, Rüdiger, Mönninghoff, Christoph, Kautzner, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754569/
https://www.ncbi.nlm.nih.gov/pubmed/30976787
http://dx.doi.org/10.1093/eurheartj/ehz190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754569/
https://www.ncbi.nlm.nih.gov/pubmed/30976787
http://dx.doi.org/10.1093/eurheartj/ehz190

Ejemplares similares